İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI:
TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ

Non-vitamin K oral antikoagülanların (NOAK) atrial fibrilasyonda inmenin önlenmesi amacıyla on yılı aşan bir süredir başarı ile kullanıldığı açıktır. Varfarine göre belirgin derecede az kanamaya yol açmaları ve inmeyi de eşit veya daha fazla oranda önleyebilmeleri yanı sıra kolay kullanım özellikleri primer proflakside atrial fibrilasyona bağlı inmeyi azaltma konusunda öne çıkmaktadır. Bunlar aynı zamanda genel inme prevalansının azalması anlamına gelmektedir. Yani AF nedenli inmenin engellenmesi toplum sağlığı için çağdaş bir gereklilik olarak algılanmalıdır. İnme klinik pratiğinde kardiyoloji uzmanları ile birlikte bu bağlamda çaba sarf eden nöroloji uzmanları için Türk Beyin Damar Hastalıkları Derneği bu uzman görüşünü hazırladı. Görüşler NOAK grubu ilaçların kullanımında sıkça karşılaşılan sorunlar ve bu problemler için güncel çözüm önerilerini içermektedir.

Anahtar Kelime:

USE OF NOAC IN CLINICAL PRACTICE OF STROKE: EXPERT OPINION OF THE TURKISH SOCIETY OF CEREBROVASCULAR DISEASES

Öz:

It is clear that nonvitamin K oral anticoagulants (NOACs) have been used successfully for more than ten years to prevent stroke in atrial fibrillation. In addition to the fact that they cause significantly less bleeding compared to warfarin and can prevent stroke equally or more, their easy-to-use features stand out in reducing stroke due to atrial fibrillation in primary prophylaxis. These also mean a decrease in the overall prevalence of stroke. For sure, prevention of AF-induced stroke should be perceived as a contemporary requirement for public health. Turkish Society of Cerebrovascular Diseases has prepared this expert opinion for neurologists who strive for this purpose together with cardiologists in the clinical practice of stroke. The article contains frequently encountered problems in the use of NOACs and current solutions for these problems.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 2011; 10(1): 61-75.
2. Wieland E, Shipkova M. Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand? Ther Drug Monit 2019; 41(2): 180-191.
3. Leung LLK. Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects. UpToDate 2020; Waltham, MA(UpToDate Inc).
4. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39(16): 1330- 1393.
5. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74(1): 104-132.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-1151.
7. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12(10): 1360-1420.
8. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-891.
9. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-992.
10. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-2104. Türk Beyin Damar Hastalıkları Dergisi 2020; 26(3): 190-235
11. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383(9921): 955-962.
12. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893- 2962.
13. Lip GYH, Collet JP, Caterina R, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2017; 19(11): 1757- 1758.
14. Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16(3): 308-319.
15. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22(20): 1852-1923.
16. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64(21): e1-76.
17. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e531S-e75S.
18. De Caterina R, Camm AJ. What is 'valvular' atrial fibrillation? A reappraisal. Eur Heart J 2014; 35(47): 3328- 3335.
19. American College of Cardiology/American Heart Association Task Force on Practice G, Society of Cardiovascular A, Society for Cardiovascular A, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114(5): e84-231.
20. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135(25): e1159-e95.
21. Hetzer R, Hill JD, Kerth WJ, Wilson AJ, Adappa MG, Gerbode F. Thrombosis and degeneration of Hancock valves: clinical and pathological findings. Ann Thorac Surg 1978; 26(4): 317-322.
22. Olesen KH. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J 1962; 24: 349-357.
23. Lester PA, Coleman DM, Diaz JA, et al. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. Arterioscler Thromb Vasc Biol 2017; 37(5): 942-948.
24. McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg 2011; 141(6): 1410-1416.
25. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369(13): 1206-1214.
26. Guimaraes PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clin Cardiol 2019; 42(5): 568-571.
27. An KR, Belley-Cote EP, Um KJ, et al. Antiplatelet Therapy versus Anticoagulation after Surgical Bioprosthetic Aortic Valve Replacement: A Systematic Review and MetaAnalysis. Thromb Haemost 2019; 119(2): 328-339.
28. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation 2015; 132(8): 624-632.
29. Breithardt G, Baumgartner H, Berkowitz SD, et al. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart 2016; 102(13): 1036-1043.
30. Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation 2016; 134(8): 589-598.
31. Kim JY, Kim SH, Myong JP, et al. Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis. J Am Coll Cardiol 2019; 73(10): 1123-1131.
32. Saposnik G, Barinagarrementeria F, Brown RD, Jr., et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42(4): 1158-1192.
33. Bose G, Graveline J, Yogendrakumar V, Fergusson D, Dowlatshahi D. Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol. Syst Rev 2019; 8(1): 99.
34. Ferro JM, Bousser MG, Canhao P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol 2017; 24(10): 1203- 1213. İnmede NOAK kullanımı
35. Wasay M, Khan M, Rajput HM, et al. New Oral Anticoagulants versus Warfarin for Cerebral Venous Thrombosis: A Multi-Center, Observational Study. J Stroke 2019; 21(2): 220-223.
36. Lee GKH, Chen VH, Tan CH, et al. Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis. J Thromb Thrombolysis 2020.
37. Caprio FZ, Bernstein RA, Alberts MJ, et al. Efficacy and safety of novel oral anticoagulants in patients with cervical artery dissections. Cerebrovasc Dis 2014; 38(4): 247-253.
38. Mustanoja S, Metso TM, Putaala J, et al. Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection. Brain Behav 2015; 5(8): e00349.
39. Cappellari M, Bovi P. Direct oral anticoagulants in patients with cervical artery dissection and cerebral venous thrombosis. A case series and review of the literature. Int J Cardiol 2017; 244: 282-284.
40. Ince B. Serebral Venöz Sinüs Trombozlarının Tedavisinde Yeni Oral Antikoagülan İlaçlar. Türk Beyin Damar Hast Derg 2016; 22(2): 49-51.
41. Cohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016; 3(9): e426-36.
42. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78(10): 1296- 1304.
43. Cohen H. The use of direct oral anticoagulants in antiphospholipid syndrome. Clin Adv Hematol Oncol 2020; 18(1): 19-23.
44. Hsu JY, Liu AB. Anticoagulants for cancer-associated ischemic stroke. Ci Ji Yi Xue Za Zhi 2019; 31(3): 144-148.
45. Wu VC, Wang CL, Huang YT, et al. Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study. J Cancer 2020; 11(1): 92-99.
46. Beyer-Westendorf J, Michalski F, Tittl L, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost 2016; 116(4): 651-658.
47. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke 2017; 48(4): 867-872.
48. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13(4): 429-438.
49. Perera KS, Vanassche T, Bosch J, et al. Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. Int J Stroke 2016; 11(5): 526-533.
50. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med 2018; 378(23): 2191-2201.
51. Diener HC, Sacco RL, Easton JD, et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med 2019; 380(20): 1906-1917.
52. Geisler T, Poli S, Meisner C, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke 2017; 12(9): 985-990.
53. Kamel H, Longstreth WT, Jr., Tirschwell DL, et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke 2019; 14(2): 207-214.
54. Karamichalakis N, Georgopoulos S, Vlachos K, et al. Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol 2016; 13(8): 718-723.
55. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest 2018; 154(5): 1121-1201.
56. Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. JAMA Cardiol 2017; 2(5): 566-574.
57. Salmonson T, Dogne JM, Janssen H, Garcia Burgos J, Blake P. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother 2017; 3(1): 42-47.
58. Di Lullo L, Ronco C, Cozzolino M, et al. Nonvitamin Kdependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thromb Res 2017; 155: 38-47.
59. Fernandez-Prado R, Castillo-Rodriguez E, Velez-Arribas FJ, Gracia-Iguacel C, Ortiz A. Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation. Am J Med 2016; 129(12): 1259-1263.
60. Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J 2019; 4(3): 198-223.
61. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation 2018; 138(15): 1519-1529.
62. Intagliata NM, Henry ZH, Maitland H, et al. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci 2016; 61(6): 1721-1727.
63. Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2013; 76(1): 89-98.
64. Duchin K, Duggal A, Atiee GJ, et al. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults. Clin Pharmacokinet 2018; 57(2): 221-228.
65. Kayaalp, S. O. : Akılcıl Tedavi Yönünden Tıbbi Farmakoloji, Gözden Geçirilmiş 13. Baskı, I. Cilt 1603 sayfa, Pelikan Kitabevi, Ankara, 2012.
66. Kayaalp SO. Akılcıl Tedavi Yönünden Tıbbi Farmakoloji, Gözden Geçirilmiş 13. Baskı, I. Cilt Ankara: Pelikan Kitabevi; 2012.
67. Pradaxa-Dabigatran. [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc 2015.
68. Peterson J, Hoehns J. Administration of Direct Oral Anticoagulants Through Enteral Feeding Tubes. Journal of Pharmacy Technology 2016; 32:196-200.(1): 196-200.
69. Xarelto-Rivaroxaban. [Package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2020. Türk Beyin Damar Hastalıkları Dergisi 2020; 26(3): 190-235
70. Eliquis-Apixaban. [Package insert]. Princeton, NJ: BristolMyers Squibb; 2019.
71. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120(15): 2954-2962.
72. Doukelis JD, Lip, G.H.Y. Perioperative management of patients receiving anticoagulants. UpToDate 2020; Waltham, MA.
73. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2019; 380(14): 1326- 1335.
74. Pollack CV, Jr., Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017; 377(5): 431-441.
75. Kuo HC, Liu FL, Chen JT, Cherng YG, Tam KW, Tai YH. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and metaanalysis. Clin Cardiol 2020; 43(5): 441-449.
76. Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 2017; 69(7): 871-898.
77. Tao J, Oprea AD. Updates in periprocedural management of direct oral anticoagulants. Curr Opin Anaesthesiol 2020; 33(3): 423-431.
78. Wiggins BS, Dixon DL, Neyens RR, Page RL, 2nd, Gluckman TJ. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol 2020; 75(11): 1341-1350.
79. commission N-Ce. NOAC GUIDELINES. http://wwwcechealthnswgovau/__data/assets/pdf_file/00 07/326419/noac_guidelinespdf 2017; (13-9-2020 ulaşıldı).
80. Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa((R)) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2013; 75(4): 1053-1562.
81. Delavenne X, Ollier E, Basset T, et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 2013; 76(1): 107-113.
82. Hartter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after comedication with rifampicin. Br J Clin Pharmacol 2012; 74(3): 490-500.
83. Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 2014; 74(11): 1209- 1231.
84. Voukalis C, Lip GY, Shantsila E. Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol 2016; 12(12): 1445-1461.
85. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013; 127(5): 634-640.
86. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2017; 38(27): 2137-2149.
87. Linnebur SA, Hanlon JT. Drug Interactions With NonVitamin K Oral Anticoagulants. JAMA 2018; 319(8): 828- 829.
88. Huisman MV, Rothman KJ, Paquette M, et al. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. Am J Med 2015; 128(12): 1306-13 e1.
89. Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol 2016; 72(3): 329-338.
90. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016; 115(1): 31-39.
91. Pottegard A, Poulsen BK, Larsen MD, Hallas J. Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study. J Thromb Haemost 2014; 12(9): 1413-1418.
92. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry. Br J Clin Pharmacol 2014; 78(4): 908-917.
93. Hellfritzsch M, Grove EL, Husted SE, et al. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. Europace 2017; 19(7): 1091-1095.
94. Ruff CT, Giugliano RP, Braunwald E, et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2014; 64(6): 576-584.
95. Granger C, Alexander J, Hanna M, Wang J, Mohan P, J L. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. Eur Heart J 2012; 33: 685- 686.
96. Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2015; 169(1): 25-30.
97. Wang KL, Lopes RD, Patel MR, et al. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J 2019; 40(19): 1492-1500.
98. Staerk L, Gerds TA, Lip GYH, et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med 2018; 283(1): 45-55.
99. Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. OnTreatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016; 134(1): 37- 47.
100. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119(10): 1363-1369.
101. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129(9): 961-970.
102. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata İnmede NOAK kullanımı preventive medicine study. Am Heart J 2009; 158(4): 629- 636.
103. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017; 38(12): 860-868.
104. Bohula EA, Giugliano RP, Ruff CT, et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AFTIMI 48 Trial. Circulation 2016; 134(1): 24-36.
105. Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2016; 1(4): 451-460.
106. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J 2017; 38(12): 852-859.
107. Wang CL, Wu VC, Chang KH, et al. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother 2020; 6(3): 147-154.
108. Mathy FX, Dohin E, Bonfitto F, Pelgrims B. Drug-drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants. Eur Heart J 2019; 40(19): 1571.
109. Potpara TS, Mujovic N, Proietti M, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: metaanalysis of pooled data from the PIONEER AF-PCI, REDUAL PCI, and AUGUSTUS trials. Europace 2020; 22(1): 33- 46.
110. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017; 23(11): 1954- 1563.
111. Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. Pharmacotherapy 2017; 37(2): 236-248.
112. Connors JM. Testing and monitoring direct oral anticoagulants. Blood 2018; 132(19): 2009-15.
113. Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018; 16(2): 209-219.
114. Gosselin RC, Adcock DM. The laboratory's 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost 2016; 14(5): 886-893.
115. Douxfils J, Dogne JM, Mullier F, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LCMS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110(3): 543-549.
116. Lessire S, Douxfils J, Baudar J, et al. Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. Thromb Res 2015; 136(3): 693- 696.
117. Frydman GH, Ellett F, Van Cott EM, et al. A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting. Crit Care Explor 2019; 1(8): e0024.
118. Douxfils J, Chatelain B, Chatelain C, Dogne JM, Mullier F. Edoxaban: Impact on routine and specific coagulation Türk Beyin Damar Hastalıkları Dergisi 2020; 26(3): 190-235 assays. A practical laboratory guide. Thromb Haemost 2016; 115(2): 368-381.
119. Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med 2015; 53(2): 185-197.
120. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogne JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012; 130(6): 956-966.
121. Bozic-Mijovski M, Malmstrom RE, Malovrh P, et al. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations. Ann Clin Biochem 2016; 53(Pt 4): 446-451.
122. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64(3): 292-303.
123. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32(2): 183-187.
124. Pratt J, Crispin P. Screening test for direct oral anticoagulants with the dilute Russell viper venom time. Eur J Haematol 2018; 100(6): 567-574.
125. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinaseinduced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 2008; 123(2): 396-403.
126. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126(20): 2381-2391.
127. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and metaanalysis of randomized controlled trials. Stroke 2012; 43(12): 3298-3304.
128. Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation 2017; 135(10): e604-e33.
129. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019; 50(12): e344-e418.
130. Xian Y, Federspiel JJ, Hernandez AF, et al. Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take NonVitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation 2017; 135(11): 1024-1035.
131. Jin C, Huang RJ, Peterson ED, et al. Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. Stroke 2018; 49(9): 2237-2240. Türk Beyin Damar Hastalıkları Dergisi 2020; 26(3): 190-235
132. Wong JWP, Churilov L, Dowling R, et al. Safety of Endovascular Thrombectomy for Acute Ischaemic Stroke in Anticoagulated Patients Ineligible for Intravenous Thrombolysis. Cerebrovasc Dis 2018; 46(5-6): 193-199.
133. Shinoda N, Mori M, Tamura S, Korosue K, Kose S, Kohmura E. Risk of Recurrent Ischemic Stroke with Unintended Low-Dose Oral Anticoagulant Therapy and Optimal Timing of Review. J Stroke Cerebrovasc Dis 2018; 27(6): 1546-1551.
134. Paciaroni M, Agnelli G, Caso V, et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke 2019; 50(8): 2168-2174.
135. Essien UR, Holmes DN, Jackson LR, 2nd, et al. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol 2018; 3(12): 1174-1182.
136. Xian Y, Hernandez AF, Harding T, et al. Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. Am Heart J 2016; 182: 28- 35.
137. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170(16): 1433-1441.
138. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366(1): 9-19.
139. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365(8): 699-708.
140. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381(9872): 1107-1115.
141. Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377(16): 1513-1524.
142. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375(25): 2423-2434.
143. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med 2019; 380(16): 1509-1524.
144. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019; 394(10206): 1335-1343.
145. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151(5): 297-305.
146. Alexander JH, Wojdyla D, Vora AN, et al. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation 2020; 141(20): 1618-1627.
147. Brott TG, Howard G, Roubin GS, et al. Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis. N Engl J Med 2016; 374(11): 1021-1031.
148. Hawkins BM, Kennedy KF, Giri J, et al. Pre-procedural risk quantification for carotid stenting using the CAS score: a report from the NCDR CARE Registry. J Am Coll Cardiol 2012; 60(17): 1617-1622.
149. Nii K, Takemura Y, Inoue R, Morinaga Y, Mitsutake T, Higashi T. Safety of direct oral anticoagulant - and antiplatelet therapy in patients with atrial fibrillation treated by carotid artery stenting. J Stroke Cerebrovasc Dis 2020; 29(7): 104899.
150. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020.
151. Hemphill JC, 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46(7): 2032-2060.
152. Schulman S, Gross PL, Ritchie B, et al. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thromb Haemost 2018; 118(5): 842-851.
153. Beinart R, Heist EK, Newell JB, Holmvang G, Ruskin JN, Mansour M. Left atrial appendage dimensions predict the risk of stroke/TIA in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22(1): 10-15.
154. Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. Heart 2014; 100(5): 396-405.
155. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12): 857-867.
156. Ding WY, Harrison S, Gupta D, Lip GYH, Lane DA. Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. Front Med (Lausanne) 2020; 7: 54.
157. Wilson D, Ambler G, Shakeshaft C, et al. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol 2018; 17(6): 539-547.
158. Baş DF, Topçuoglu MA, Arsava EM. Yeni antikoagülasyonlar perspektifinde atriyal fibrilasyon ve inme. Türk Beyin Damar Hastalıkları Dergisi 2013; 19(2): 35-45.
159. Aytemiz F. Atriyal Fibrilasyonda Antikoagülan Tedavi ve Yeni Oral Antikoagülan İlaçlar. Türkiye Klinikleri Kardiyoloji-Özel Konular 2015; 8(1): 28-42.
160. Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with nonvalvular atrial fibrillation: a population-based cohort study. Europace 2018; 20(3): 420-428.
161. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33(12): 1500- 1510. İnmede NOAK kullanımı
162. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HASBLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57(2): 173-180.
163. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1- year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093-1100.
164. Zulkifly H, Lip GYH, Lane DA. Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. Am J Cardiol 2017; 120(7): 1139-1145.
165. Chao TF, Lip GYH, Lin YJ, et al. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. Int J Cardiol 2018; 254: 157-161.
166. Lioutas VA, Goyal N, Katsanos AH, et al. Optimization of risk stratification for anticoagulation-associated intracerebral hemorrhage: net risk estimation. J Neurol 2020; 267(4): 1053-1062.
167. İlacaBak. Pradaxa, Xeralto, Eliquis, Lixiana prospektüs bilgileri. 2020. https://www.ilacabak.com/pradaxa-110- mg-10-sert-kapsul-12312/kisa-urun-bilgisi, https://www.ilacabak.com/pradaxa-150-mg-60-sertkapsul-13945/kisa-urun-bilgisi, https://www.ilacabak.com/xarelto-20-mg-28-film-kaplitablet-14930/kisa-urun-bilgisi, https://www.ilacabak.com/lixiana-60-mg-28-film-kaplitablet-18911/kisa-urun-bilgisi, https://www.ilacabak.com/eliquis-5-mg-film-kapli-tablet56-tablet-23379/kisa-urun-bilgisi (accessed 19.9.2020.
168. TCSB. 16.06.2020 Değişiklik Tebliği İşlenmiş Güncel 2013 Sağlık Uygulama Tebliği (SUT). 2020. http://www.sgk.gov.tr/wps/portal/sgk/tr/kurumsal/mer kezteskilati/ana_hizmet_birimleri/gss_genel_mudurlugu/anas ayfa_duyurular/duyuru_20200603_20 (accessed 19-9- 2020.

APA	Acar B, akpınar c, Alioglu Z, arlier z, Arsava E, aytac e, Bas D, Baydemir R, Cabalar M, Çevik M, EREN A, GİRAY S, GUNGOR I, Gürkaş E, Kayim Yildiz O, Kozak H, Midi I, Milanlıoğlu A, Nazliel B, ögün m, Özdemir A, Ozkul A, Ozturk S, Öztürk V, SARIONDER GENCER E, SIRIN H, TOGAY ISIKAY C, TOPCUOGLU M, TÜFEKÇİ A, ÜNAL A, Yaka E, Yurekli V (2020). İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. , 190 - 235. 10.5505/tbdhd.2020.26213
Chicago	Acar Bilgehan,akpınar cetin kursad,Alioglu Zekeriya,arlier zulfikar,Arsava Ethem Murat,aytac emrah,Bas Demet Funda,Baydemir Recep,Cabalar Murat,Çevik Mehmet uğur,EREN ALPER,GİRAY Semih,GUNGOR IBRAHIM LEVENT,Gürkaş Erdem,Kayim Yildiz Ozlem,Kozak Hasan Hüseyin,Midi Ipek,Milanlıoğlu Aysel,Nazliel Bijen,ögün muhammed nur,Özdemir Atilla Özcan,Ozkul Ayca,Ozturk Serefnur,Öztürk Vesile,SARIONDER GENCER ELIF,SIRIN HADIYE,TOGAY ISIKAY CANAN,TOPCUOGLU MEHMET,TÜFEKÇİ AHMET,ÜNAL ALİ,Yaka Erdem,Yurekli Vedat Ali İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. (2020): 190 - 235. 10.5505/tbdhd.2020.26213
MLA	Acar Bilgehan,akpınar cetin kursad,Alioglu Zekeriya,arlier zulfikar,Arsava Ethem Murat,aytac emrah,Bas Demet Funda,Baydemir Recep,Cabalar Murat,Çevik Mehmet uğur,EREN ALPER,GİRAY Semih,GUNGOR IBRAHIM LEVENT,Gürkaş Erdem,Kayim Yildiz Ozlem,Kozak Hasan Hüseyin,Midi Ipek,Milanlıoğlu Aysel,Nazliel Bijen,ögün muhammed nur,Özdemir Atilla Özcan,Ozkul Ayca,Ozturk Serefnur,Öztürk Vesile,SARIONDER GENCER ELIF,SIRIN HADIYE,TOGAY ISIKAY CANAN,TOPCUOGLU MEHMET,TÜFEKÇİ AHMET,ÜNAL ALİ,Yaka Erdem,Yurekli Vedat Ali İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. , 2020, ss.190 - 235. 10.5505/tbdhd.2020.26213
AMA	Acar B,akpınar c,Alioglu Z,arlier z,Arsava E,aytac e,Bas D,Baydemir R,Cabalar M,Çevik M,EREN A,GİRAY S,GUNGOR I,Gürkaş E,Kayim Yildiz O,Kozak H,Midi I,Milanlıoğlu A,Nazliel B,ögün m,Özdemir A,Ozkul A,Ozturk S,Öztürk V,SARIONDER GENCER E,SIRIN H,TOGAY ISIKAY C,TOPCUOGLU M,TÜFEKÇİ A,ÜNAL A,Yaka E,Yurekli V İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. . 2020; 190 - 235. 10.5505/tbdhd.2020.26213
Vancouver	Acar B,akpınar c,Alioglu Z,arlier z,Arsava E,aytac e,Bas D,Baydemir R,Cabalar M,Çevik M,EREN A,GİRAY S,GUNGOR I,Gürkaş E,Kayim Yildiz O,Kozak H,Midi I,Milanlıoğlu A,Nazliel B,ögün m,Özdemir A,Ozkul A,Ozturk S,Öztürk V,SARIONDER GENCER E,SIRIN H,TOGAY ISIKAY C,TOPCUOGLU M,TÜFEKÇİ A,ÜNAL A,Yaka E,Yurekli V İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. . 2020; 190 - 235. 10.5505/tbdhd.2020.26213
IEEE	Acar B,akpınar c,Alioglu Z,arlier z,Arsava E,aytac e,Bas D,Baydemir R,Cabalar M,Çevik M,EREN A,GİRAY S,GUNGOR I,Gürkaş E,Kayim Yildiz O,Kozak H,Midi I,Milanlıoğlu A,Nazliel B,ögün m,Özdemir A,Ozkul A,Ozturk S,Öztürk V,SARIONDER GENCER E,SIRIN H,TOGAY ISIKAY C,TOPCUOGLU M,TÜFEKÇİ A,ÜNAL A,Yaka E,Yurekli V "İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ." , ss.190 - 235, 2020. 10.5505/tbdhd.2020.26213
ISNAD	Acar, Bilgehan vd. "İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ". (2020), 190-235. https://doi.org/10.5505/tbdhd.2020.26213

APA	Acar B, akpınar c, Alioglu Z, arlier z, Arsava E, aytac e, Bas D, Baydemir R, Cabalar M, Çevik M, EREN A, GİRAY S, GUNGOR I, Gürkaş E, Kayim Yildiz O, Kozak H, Midi I, Milanlıoğlu A, Nazliel B, ögün m, Özdemir A, Ozkul A, Ozturk S, Öztürk V, SARIONDER GENCER E, SIRIN H, TOGAY ISIKAY C, TOPCUOGLU M, TÜFEKÇİ A, ÜNAL A, Yaka E, Yurekli V (2020). İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. Türk Beyin Damar Hastalıkları Dergisi, 26(3), 190 - 235. 10.5505/tbdhd.2020.26213
Chicago	Acar Bilgehan,akpınar cetin kursad,Alioglu Zekeriya,arlier zulfikar,Arsava Ethem Murat,aytac emrah,Bas Demet Funda,Baydemir Recep,Cabalar Murat,Çevik Mehmet uğur,EREN ALPER,GİRAY Semih,GUNGOR IBRAHIM LEVENT,Gürkaş Erdem,Kayim Yildiz Ozlem,Kozak Hasan Hüseyin,Midi Ipek,Milanlıoğlu Aysel,Nazliel Bijen,ögün muhammed nur,Özdemir Atilla Özcan,Ozkul Ayca,Ozturk Serefnur,Öztürk Vesile,SARIONDER GENCER ELIF,SIRIN HADIYE,TOGAY ISIKAY CANAN,TOPCUOGLU MEHMET,TÜFEKÇİ AHMET,ÜNAL ALİ,Yaka Erdem,Yurekli Vedat Ali İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. Türk Beyin Damar Hastalıkları Dergisi 26, no.3 (2020): 190 - 235. 10.5505/tbdhd.2020.26213
MLA	Acar Bilgehan,akpınar cetin kursad,Alioglu Zekeriya,arlier zulfikar,Arsava Ethem Murat,aytac emrah,Bas Demet Funda,Baydemir Recep,Cabalar Murat,Çevik Mehmet uğur,EREN ALPER,GİRAY Semih,GUNGOR IBRAHIM LEVENT,Gürkaş Erdem,Kayim Yildiz Ozlem,Kozak Hasan Hüseyin,Midi Ipek,Milanlıoğlu Aysel,Nazliel Bijen,ögün muhammed nur,Özdemir Atilla Özcan,Ozkul Ayca,Ozturk Serefnur,Öztürk Vesile,SARIONDER GENCER ELIF,SIRIN HADIYE,TOGAY ISIKAY CANAN,TOPCUOGLU MEHMET,TÜFEKÇİ AHMET,ÜNAL ALİ,Yaka Erdem,Yurekli Vedat Ali İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. Türk Beyin Damar Hastalıkları Dergisi, vol.26, no.3, 2020, ss.190 - 235. 10.5505/tbdhd.2020.26213
AMA	Acar B,akpınar c,Alioglu Z,arlier z,Arsava E,aytac e,Bas D,Baydemir R,Cabalar M,Çevik M,EREN A,GİRAY S,GUNGOR I,Gürkaş E,Kayim Yildiz O,Kozak H,Midi I,Milanlıoğlu A,Nazliel B,ögün m,Özdemir A,Ozkul A,Ozturk S,Öztürk V,SARIONDER GENCER E,SIRIN H,TOGAY ISIKAY C,TOPCUOGLU M,TÜFEKÇİ A,ÜNAL A,Yaka E,Yurekli V İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. Türk Beyin Damar Hastalıkları Dergisi. 2020; 26(3): 190 - 235. 10.5505/tbdhd.2020.26213
Vancouver	Acar B,akpınar c,Alioglu Z,arlier z,Arsava E,aytac e,Bas D,Baydemir R,Cabalar M,Çevik M,EREN A,GİRAY S,GUNGOR I,Gürkaş E,Kayim Yildiz O,Kozak H,Midi I,Milanlıoğlu A,Nazliel B,ögün m,Özdemir A,Ozkul A,Ozturk S,Öztürk V,SARIONDER GENCER E,SIRIN H,TOGAY ISIKAY C,TOPCUOGLU M,TÜFEKÇİ A,ÜNAL A,Yaka E,Yurekli V İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ. Türk Beyin Damar Hastalıkları Dergisi. 2020; 26(3): 190 - 235. 10.5505/tbdhd.2020.26213
IEEE	Acar B,akpınar c,Alioglu Z,arlier z,Arsava E,aytac e,Bas D,Baydemir R,Cabalar M,Çevik M,EREN A,GİRAY S,GUNGOR I,Gürkaş E,Kayim Yildiz O,Kozak H,Midi I,Milanlıoğlu A,Nazliel B,ögün m,Özdemir A,Ozkul A,Ozturk S,Öztürk V,SARIONDER GENCER E,SIRIN H,TOGAY ISIKAY C,TOPCUOGLU M,TÜFEKÇİ A,ÜNAL A,Yaka E,Yurekli V "İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ." Türk Beyin Damar Hastalıkları Dergisi, 26, ss.190 - 235, 2020. 10.5505/tbdhd.2020.26213
ISNAD	Acar, Bilgehan vd. "İNME KLİNİK PRATİĞİNDE NOAK KULLANIMI: TÜRK BEYİN DAMAR HASTALIKLARI DERNEĞİ UZMAN GÖRÜŞÜ". Türk Beyin Damar Hastalıkları Dergisi 26/3 (2020), 190-235. https://doi.org/10.5505/tbdhd.2020.26213